Elicio Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
Rhea-AI Summary
Elicio Therapeutics (Nasdaq: ELTX) announced that CEO Robert Connelly and CSO Pete DeMuth will present at the TD Cowen 46th Annual Health Care Conference in Boston, March 2-4, 2026. The company presentation is scheduled for March 4, 2026 at 1:10 PM ET.
According to Elicio, a live webcast and a 90-day replay will be available on the company Events page for investors who cannot attend in person.
Positive
- None.
Negative
- None.
News Market Reaction – ELTX
On the day this news was published, ELTX gained 10.35%, reflecting a significant positive market reaction. Argus tracked a peak move of +14.6% during that session. Our momentum scanner triggered 12 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $19M to the company's valuation, bringing the market cap to $207M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Momentum scanner shows mixed peer moves: CCCC up 5.02% while KYTX down 2.01%, with no broad, same-direction sector push indicated.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 18 | Inducement grants | Neutral | +3.4% | Granted 30,300 inducement stock options at $8.59 with four-year vesting. |
| Jan 16 | Inducement grants | Neutral | +5.6% | Granted 22,400 inducement options at $7.81 under 2024 plan. |
| Dec 16 | Inducement grants | Neutral | -4.3% | Granted 157,193 inducement options at $8.52 to three new employees. |
| Dec 11 | Clinical trial update | Positive | +4.0% | Phase 2 AMPLIFY-7P data showed broad T cell responses and antigen spreading. |
| Nov 19 | Executive appointment | Positive | -5.5% | Appointed CTO to lead CMC and operations ahead of ELI-002 7P DFS analysis. |
Recent news skewed to inducement grants and management updates, with modest price moves usually aligning with the news tone, except for one negative reaction to a CTO appointment.
Over the last few months, Elicio has mainly reported inducement stock option grants and governance moves, alongside one notable Phase 2 AMPLIFY-7P update showing strong T cell responses. Inducement grants in Dec 2025–Feb 2026 saw generally small price gains or losses. A Nov 19, 2025 CTO appointment tied to preparations for the ELI-002 7P disease‑free survival analysis in 1H 2026 drew a negative reaction. Today’s conference participation fits within this cadence of corporate and investor-relations oriented news.
Regulatory & Risk Context
An effective S-3 resale registration filed on Nov 13, 2025 covers up to 103,225 common shares issuable upon exercise of a warrant with a $7.75 exercise price and a 49.99% beneficial ownership cap. The company would receive cash proceeds only if the warrant is exercised; sales by the selling stockholder themselves do not generate proceeds for Elicio.
Market Pulse Summary
The stock surged +10.3% in the session following this news. A strong positive reaction aligns with the stock’s recent pattern of constructive responses to news, such as prior clinical updates showing meaningful T cell activity. However, this conference appearance is mainly an investor-relations event, not a new data readout. With short interest around 19.72% and a relatively small float, squeezes and sharp reversals have been possible when sentiment or liquidity shifts.
Key Terms
immunotherapies medical
AI-generated analysis. Not financial advice.
BOSTON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that Robert Connelly, Chief Executive Officer, and Pete DeMuth, PhD, Chief Scientific Officer, will participate in the upcoming TD Cowen 46th Annual Health Care Conference, taking place March 2-4, 2026, in Boston, MA.
TD Cowen 46th Annual Health Care Conference
Format: Company presentation
Date: Wednesday, March 4, 2026
Time: 1:10 PM ET
The live webcast and replay of the presentation will be available HERE and on Elicio’s Events page for 90 days following the event.
If you are interested in arranging a 1×1 meeting with management at the conference, please contact your TD Cowen representative.
About Elicio Therapeutics
Elicio Therapeutics, Inc. (Nasdaq: ELTX) is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of high-prevalence cancers, including mKRAS-positive pancreatic and colorectal cancers. Elicio intends to build on recent clinical successes in the personalized cancer immunotherapy space to develop effective, off-the-shelf immunotherapies. Elicio’s Amphiphile (“AMP”) technology aims to enhance the education, activation and amplification of cancer-specific T cells relative to conventional immunotherapy strategies, with the goal of promoting durable cancer immunosurveillance in patients. Elicio’s ELI-002 7P lead program is an off-the-shelf immunotherapy candidate targeting the most common KRAS mutations, which drives approximately
Investor Relations Contact
Brian Ritchie
LifeSci Advisors
(212) 915-2578
britchie@lifesciadvisors.com
FAQ
When will Elicio (ELTX) present at the TD Cowen Health Care Conference in 2026?
Who from Elicio (ELTX) will speak at the TD Cowen 46th Annual Health Care Conference?
How can investors watch Elicio's (ELTX) March 4, 2026 presentation online?
Can investors request a 1×1 meeting with Elicio (ELTX) management at the TD Cowen conference?
What topics will Elicio (ELTX) likely cover at the March 4, 2026 company presentation?
Where will the replay of Elicio's (ELTX) TD Cowen presentation be available and for how long?
